Orgenesis Inc. (ORGS) Stock Analysis

Orgenesis Inc. (ORGS) Healthcare & Pipeline Overview

Orgenesis Inc. is a biotechnology firm specializing in cell and gene therapies through its proprietary Point of Care (POCare) platform. The company develops and delivers autologous therapies via closed, automated systems, positioning it within the evolving landscape of personalized medicine and decentralized healthcare solutions.

What Is the Investment Thesis for ORGS?

Orgenesis Inc. presents a unique investment opportunity within the cell and gene therapy space, driven by its innovative Point of Care (POCare) platform. The company's focus on autologous therapies and decentralized manufacturing aims to address key challenges in the delivery of advanced treatments. However, the company's negative profit margin of -10445.5% and gross margin of -1080.2% indicate significant financial challenges. The high beta of 4.07 suggests high volatility. Upcoming catalysts include the potential for regulatory approvals and commercialization of its POCare therapeutics. The success of its collaborative POCare network and the adoption of its closed, automated processing systems will be critical for long-term growth. Investors should carefully consider the company's financial performance and the risks associated with operating in the highly competitive biotechnology industry.

Based on FMP financials and quantitative analysis

ORGS Key Highlights

Orgenesis Inc. operates in the high-growth cell and gene therapy market.

• The company's Point of Care (POCare) platform aims to decentralize the production of advanced therapies.
• Focus on autologous therapies reduces the risk of immune rejection.
• Negative profit margin of -10445.5% indicates significant financial challenges.
• High beta of 4.07 suggests high stock price volatility.

Who Are ORGS's Competitors?

ORGS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are ORGS's Key Strengths?

Proprietary Point of Care (POCare) platform.

• Focus on autologous therapies.
• Decentralized manufacturing model.
• Collaborative POCare network.

What Are ORGS's Weaknesses?

Negative profit margin.

• High operating expenses.
• Limited commercialized products.
• Reliance on partnerships for growth.

What Could Drive ORGS Stock Higher?

Regulatory approvals for POCare therapeutics.

• Expansion of POCare network.
• Strategic partnerships with pharmaceutical companies.
• Technological advancements to enhance POCare platform.

What Are the Key Risks for ORGS?

Financial-distress signal — its Altman Z-Score of -19.17 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 4 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Competition from established pharmaceutical companies.
• Regulatory hurdles and delays.
• Technological obsolescence.
• Negative profit margin.
• High operating expenses.

What Are the Growth Opportunities for ORGS?

• Expansion of POCare Network: Orgenesis has the opportunity to expand its collaborative POCare network by partnering with hospitals and research institutions globally. This expansion would increase the accessibility of its cell and gene therapies, driving revenue growth. The global cell therapy market is projected to reach $8.28 billion in 2024 and is expected to grow. Timeline: Ongoing.
• Regulatory Approvals: Securing regulatory approvals for its pipeline of POCare therapeutics represents a significant growth opportunity. Successful approvals would validate the efficacy and safety of its therapies, leading to increased adoption and market penetration. The timeline for regulatory approvals varies depending on the specific therapy and regulatory pathway. Timeline: Upcoming.
• Strategic Partnerships: Forming strategic partnerships with pharmaceutical companies and other healthcare providers can accelerate the development and commercialization of its therapies. These partnerships can provide access to funding, expertise, and distribution channels. The timeline for forming strategic partnerships is dependent on identifying suitable partners and negotiating mutually beneficial agreements. Timeline: Ongoing.
• Technological Advancements: Investing in technological advancements to enhance its POCare platform can improve the efficiency and scalability of its manufacturing processes. This includes automation, closed systems, and advanced analytics. The timeline for implementing technological advancements is dependent on the specific technology and the availability of resources. Timeline: Ongoing.
• Geographic Expansion: Expanding its operations into new geographic markets represents a significant growth opportunity. This includes establishing POCare centers in regions with unmet medical needs and growing demand for advanced therapies. The timeline for geographic expansion is dependent on market analysis, regulatory approvals, and resource allocation. Timeline: Ongoing.

What Are ORGS's Competitive Advantages?

• Proprietary Point of Care (POCare) platform.
• Closed and automated processing systems.
• Collaborative POCare network.
• Focus on autologous therapies.

What Does ORGS Do?

Orgenesis Inc., established in 2008 and headquartered in Germantown, Maryland, is a biotechnology company dedicated to advancing cell and gene therapies. Originally named Business Outsourcing Service, Inc., the company rebranded to Orgenesis Inc. in August 2011, marking a strategic shift towards the healthcare sector. Orgenesis focuses on developing and deploying its Point of Care (POCare) platform, a comprehensive system designed for the localized production and delivery of advanced therapies. This platform includes a pipeline of licensed POCare therapeutics, which are processed and produced in closed, automated POCare technology systems. These systems are integrated within a collaborative POCare network, enabling the efficient and compliant manufacturing of therapies near the patient's point of care. The company's primary focus is on autologous therapies, where a patient's own cells are used for treatment, thereby reducing the risk of rejection and enhancing therapeutic efficacy. Orgenesis's approach involves developing customized processes and systems for each therapy, ensuring that the production is validated for compliant manufacturing. This decentralized model aims to improve patient access to advanced therapies, reduce costs, and enhance treatment outcomes.

What Products and Services Does ORGS Offer?

• Develops Point of Care (POCare) platform for cell and gene therapies.
• Focuses on autologous therapies using patient's own cells.
• Creates closed and automated processing systems for therapy production.
• Establishes collaborative POCare networks for decentralized manufacturing.
• Aims to improve patient access to advanced therapies.
• Validates processes for compliant production near the patient.

How Does ORGS Make Money?

• Develops and licenses POCare therapeutics.
• Generates revenue through the sale of POCare technology systems.
• Forms partnerships with hospitals and research institutions.
• Provides training and support for POCare network members.

What Industry Does ORGS Operate In?

Orgenesis Inc. operates within the rapidly evolving cell and gene therapy market, a sector characterized by significant innovation and growth potential. The industry is driven by advancements in biotechnology and a growing demand for personalized medicine. Companies like Orgenesis are at the forefront of developing novel therapies for a range of diseases, including cancer and genetic disorders. The competitive landscape includes established pharmaceutical companies, as well as emerging biotech firms, all vying for market share. Orgenesis's Point of Care (POCare) platform differentiates it by enabling decentralized manufacturing, potentially reducing costs and improving patient access. The market is expected to continue to grow, driven by increasing regulatory approvals and commercialization of new therapies.

Who Are ORGS's Key Customers?

• Hospitals and medical centers.
• Research institutions and universities.
• Pharmaceutical companies.
• Patients requiring cell and gene therapies.

Orgenesis Inc. Financial Trajectory

Orgenesis Inc. (ORGS) reported $347K in revenue for Q3 FY2024, reflecting 41.1% growth compared to the prior quarter. The company recorded net income of $9.1M, with diluted EPS of $0.19. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this unknown Healthcare company.

Company Profile

Orgenesis Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Germantown, US. The company is led by CEO Vered Caplan. ORGS has traded publicly since 2012.

Orgenesis Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -19.17 places it in the distress zone, a signal of elevated financial risk.

Orgenesis Inc. has missed Wall Street's EPS estimate in 4 of its last 4 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 394.5% below estimates on average.

The most recent 10 insider filings for Orgenesis Inc. break down as 0 sales and 10 purchases. On net that is roughly 253K shares acquired (about $260K) — insiders putting money in tends to read as conviction.

ORGS Financials

ORGS Latest News

ORGS Analyst Consensus

ORGS MoonshotScore

What Investors Ask About Orgenesis Inc. (ORGS) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources